医学
肺动脉高压
重症监护医学
临床实习
心脏病学
梅德林
内科学
物理疗法
政治学
法学
作者
Katarina Zeder,Evan L. Brittain,Gábor Kovács,Bradley A. Maron
出处
期刊:Annals of the American Thoracic Society
[American Thoracic Society]
日期:2024-05-15
卷期号:21 (8): 1115-1123
被引量:3
标识
DOI:10.1513/annalsats.202312-1079fr
摘要
The definition of pulmonary hypertension (PH) has been revised recently, with the mean pulmonary artery pressure (mPAP) threshold (assessed by right heart catheterization) reduced from ⩾25 mm Hg to >20 mm Hg. This change reflects the mPAP upper limit of normal and a lower limit that is independently associated with adverse outcomes. To improve the specificity of diagnosing pathogenic increases in mPAP, however, a diagnosis of precapillary PH now also includes pulmonary vascular resistance >2.0 Wood units (WU) (lowered from >3.0 WU). These changes are positioned to capture approximately 55% more patients with PH. Because all clinical trials showing a benefit of pulmonary vasodilator therapy in precapillary PH used the classical hemodynamic definition, the approach to the diagnosis and management of patients with mild PH (i.e., mPAP 21-24 mm Hg and pulmonary vascular resistance 2-3 WU) requires particular consideration. Here, we use a question/answer format to discuss key areas in the management of mild PH, including practical information tailored to clinicians without training in PH.
科研通智能强力驱动
Strongly Powered by AbleSci AI